CLAIRE FAUST NICHOLS: Open Payments
NPI 1386293272 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,739 in 93 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $139 · 2025 $1,739
Food & beverage: $1,739
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $462 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $334 |
| Vanda Pharmaceuticals Inc. | 12 | $181 |
| Otsuka America Pharmaceutical, Inc. | 8 | $144 |
| Teva Pharmaceuticals USA, Inc. | 5 | $136 |
| E.R. Squibb & Sons, L.L.C. | 4 | $106 |
| Janssen Pharmaceuticals, Inc | 3 | $77 |
| Tris Pharma Inc | 4 | $69 |
| Supernus Pharmaceuticals, Inc. | 3 | $63 |
| Indivior Inc. | 1 | $41 |
Products named: VRAYLAR, CAPLYTA, FANAPT, AUSTEDO XR, COBENFY, SPRAVATO, REXULTI, Dyanavel XR.
Industry payments across NV — which companies pay providers there.
